You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CARDINAL HEALTH 414 Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?

CARDINAL HEALTH 414 has five approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

There are thirty patent family members on CARDINAL HEALTH 414 drugs in twelve countries and seventy-one supplementary protection certificates in nine countries.

Summary for CARDINAL HEALTH 414
International Patents:30
US Patents:2
Tradenames:5
Ingredients:5
NDAs:5

Drugs and US Patents for CARDINAL HEALTH 414

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414 FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 203603-002 Sep 27, 2018 AP RX No No ⤷  Try a Trial ⤷  Try a Trial
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes 9,439,985 ⤷  Try a Trial Y ⤷  Try a Trial
Cardinal Health 414 TECHNETIUM TC 99M SESTAMIBI technetium tc-99m sestamibi kit INJECTABLE;INJECTION 078809-001 Apr 28, 2009 AP RX No No ⤷  Try a Trial ⤷  Try a Trial
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes 6,409,990 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CARDINAL HEALTH 414 Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1856135 LUC00153 Luxembourg ⤷  Try a Trial PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
1912999 2014/058 Ireland ⤷  Try a Trial PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
2203431 CR 2015 00014 Denmark ⤷  Try a Trial PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
2203431 15C0013 France ⤷  Try a Trial PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.